Longitudinal Study of Different Progression Patterns in High-Risk Cutaneous Squamous Cell Carcinoma.

ESTUDIO LONGITUDINAL DE LOS DIFERENTES PATRONES DE PROGRESIÓN EN EL CARCINOMA CUTÁNEO DE CÉLULAS ESCAMOSAS DE ALTO RIESGO.
Cutaneous squamous cell carcinoma Disease progression Lymphatic metastasis Neoplastic metastasis Prognosis carcinoma cutáneo de células escamosas metástasis linfática metástasis neoplásica progresión de la enfermedad pronóstico

Journal

Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062

Informations de publication

Date de publication:
28 Mar 2024
Historique:
received: 15 09 2023
accepted: 11 03 2024
medline: 31 3 2024
pubmed: 31 3 2024
entrez: 30 3 2024
Statut: aheadofprint

Résumé

Cutaneous squamous cell carcinoma (cSCC) is the second leading cause of skin cancer mortality in Europe. Few studies have analyzed the different pathways of this tumor progression in its natural history. The main objective of this study was to analyze the different metastatic and progression pathways and their temporal occurrence in the evolution of cSCC. We conducted a multicenter, retrospective, and observational study of consecutive high-risk sSCCs included in the SQUAMATA project. A total of 222 out of the 1346 patients included relapsed. The most frequent route of progression was the lymphatic one (62.6%). A total of 20.2% of the cases with lymphatic progression developed distant metastases. Only 1 case (3.1%) of distant metastasis followed local recurrence without previous lymphatic metastasis. The median time to disease-related mortality was longer in patients who developed systemic metastases than in those who died of locoregional progression. The mortality of patients with cSCC is mostly due to the regional progression of their lymphatic metastases. The appearance of distant metastases is practically always (96.9%) associated with previous lymphatic metastatic progression. Therefore, in the future, new studies will be needed to assess the regional management of cSCC in both surgical and adjuvant therapies.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Cutaneous squamous cell carcinoma (cSCC) is the second leading cause of skin cancer mortality in Europe. Few studies have analyzed the different pathways of this tumor progression in its natural history. The main objective of this study was to analyze the different metastatic and progression pathways and their temporal occurrence in the evolution of cSCC.
MATERIAL AND METHOD METHODS
We conducted a multicenter, retrospective, and observational study of consecutive high-risk sSCCs included in the SQUAMATA project.
RESULTS RESULTS
A total of 222 out of the 1346 patients included relapsed. The most frequent route of progression was the lymphatic one (62.6%). A total of 20.2% of the cases with lymphatic progression developed distant metastases. Only 1 case (3.1%) of distant metastasis followed local recurrence without previous lymphatic metastasis. The median time to disease-related mortality was longer in patients who developed systemic metastases than in those who died of locoregional progression.
CONCLUSIONS CONCLUSIONS
The mortality of patients with cSCC is mostly due to the regional progression of their lymphatic metastases. The appearance of distant metastases is practically always (96.9%) associated with previous lymphatic metastatic progression. Therefore, in the future, new studies will be needed to assess the regional management of cSCC in both surgical and adjuvant therapies.

Identifiants

pubmed: 38554750
pii: S0001-7310(24)00263-1
doi: 10.1016/j.ad.2024.03.018
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

A Tejera-Vaquerizo (A)

Unidad de Oncología Cutánea. Hospital San Juan de Dios, Córdoba, Spain; Servicio de Dermatología. Instituto Dermatológico GlobalDerm. Palma del Río (Córdoba), España. Electronic address: antoniotejera@aedv.es.

J Cañueto (J)

Servicio de Dermatología. Complejo Asistencial Universitario de Salamanca, Salamanca, España.

Á Gómez-Tomás (Á)

Servicio de Dermatología. Hospital Universitari Vall d'Hebron Universidad Autónoma de Barcelona, Barcelona, España.

J Santos-Juanes (J)

Servicio de Dermatología. Hospital Central de Asturias e Instituto de Investigación Sanitaria del Principado de Asturias, IUOPA, Universidad de Oviedo, Oviedo, España.

S Ribero (S)

Medical Sciences Department, Section of Dermatology, University of Turin, Turin, Italy.

G Avallone (G)

Medical Sciences Department, Section of Dermatology, University of Turin, Turin, Italy.

A Jaka (A)

Servicio de Dermatología. Hospital Universitari Germans Trials i Pujol, Institut d'Investigació GermansTrias i Pujol. Universitat Autònoma de Barcelona, Badalona, España.

C Ferrandiz-Pulido (C)

Servicio de Dermatología. Hospital Universitari Vall d'Hebron Universidad Autónoma de Barcelona, Barcelona, España.

A Toll (A)

Servicio de Dermatología. Hospital Clínic de Barcelona. Universitat de Barcelona, Barcelona, España.

O Sanmartín (O)

Servicio de Dermatología. Instituto Valenciano de Oncología, Valencia, España.

Classifications MeSH